Overall, it is evident that proteomic and MS-based technologies have yielded an indispensable amount of information, which has been useful for the understanding of proteomic alterations that occur during OvCa pathogenesis. In terms of diagnostics, the use of shotgun proteomics selleck products has been relatively disappointing due to the wealth of novel markers “identified”, yet few have passed clinical validation. The lack of markers has thus necessitated this surge of innovative MS-based biomarker discovery techniques such as glycomics and metabolomics. Whether

or not these techniques will identify the elusive novel biomarker(s) for OvCa remains to be seen as the majority of the approaches, however promising,

are still in their infancy and there still exists many technical limitations that have yet to be overcome. On the other hand, proteomic studies aimed at identifying markers of therapeutic response are only beginning to emerge. Although several mechanisms of chemoresistance and potential markers of drug response have been unravelled, these studies are also subjected to their own biases and limitations. Future efforts should focus on using biologically relevant samples that capture the heterogeneity AZD2281 of the disease, as well validating findings in independent sample cohorts. “
“In contemporary practice, most patients with prostate

cancer (PCa) are diagnosed following a PSA test and are asymptomatic at the time of diagnosis. Although serum PSA has a low specificity for prostate cancer, it can be used to single out patients with advanced disease. Efforts BCKDHB to improve our understanding of disease onset, diagnosis and progression through the analysis of prostate tissue, serum, plasma, urine or seminal fluid offers various entry points for discovery driven analysis. One of these is proteomics that aims at the determination of protein constituents and their isoforms in a give sample [1]. For this type of analysis several technologies are available to allow high-throughput analysis of prostate cancer samples. This includes affinity-based proteomics with a growing number of available binding molecules toward human proteins [2], and combined with microarray assays, multi-parallel immunoassays of many samples can be achieved [3]. In a previous study, we used antibodies from the Human Protein Atlas [4] and suspension bead arrays [5] to protein profile plasma from patients with prostate cancer and respective controls. There we identified the protein carnosine dipeptidase 1 (CNDP1), as a potential marker for aggressive prostate cancer.